Abstract
To compare survival rates and long-term complications after bone marrow transplantation (BMT) or treatment with immunosuppressive agents (ISA) in the management of adult aplastic anemia (AA) and to identify prognostic factors associated with improved survival, we evaluated 229 adult AA patients treated with ISA from 1990 to 2001 and compared the results with those for 64 BMT recipients. Of 156 patients with severe aplastic anemia (SAA) or very severe AA treated with ISA (antithymocyte globulin [ATG]or ATG plus cyclosporine), 46.8% showed complete or partial response and 7.1% had relapses. After long-term follow-up, 1 case each of acute leukemia, myelodysplastic syndrome, and paroxysmal nocturnal hemoglobinuria developed.The 6-year survival rate was 69%. Response to ISA, disease severity, and low absolute neutrophil count (ANC) (≤200/mm3) were associated with poor survival. Patient age, sex, initial platelet count, etiology, or treatment regimen did not significantly affect survival. Cox regression analysis showed low ANC to be the only pretreatment variable significantly associated with poor survival (P = .000). Of 64 BMT recipients, 82.8% had sustained engraftment, and 12.5% experienced graft failure. Twenty (31.3%) of the patients developed grade II to IV acute graft-versus-host disease (GVHD), and 12 (18.8%) of the patients developed chronic GVHD.The 6-year survival rate was 79%. Patient age and sex, disease severity, etiology,ANC, initial platelet count, and treatment regimen did not affect survival. Survival of 83 AA patients, aged 14 to 40 years, treated with ISA was not statistically significant from that of 61 adult AA patients who underwent BMT (6-year survival rate, 65% and 79%, respectively). However, BMT in adult AA achieved long-term engraftment and a lower relapse rate than ISA.These results suggest that ISA can achieve a high response rate and long-term survival among patients with adult AA,regardless of disease severity. Further studies with larger numbers of patients and long-term follow-up are needed.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Barrett AJ, Young NS. The treatment of severe acquired aplastic anemia.Blood. 1995;85:3367–3377.
Deeg HJ, Leisenring W, Storb R, et al. Long-term outcome after marrow transplantation for severe aplastic anemia.Blood. 1998;91:3637–3645.
Passweg JR, Socie G, Hinterberger W, et al. Bone marrow transplantation for severe aplastic anemia: has outcome improved?Blood. 1997;90:858–864.
Socie G, Stone JV, Wingard JR, et al. Long-term survival and late deaths after allogeneic bone marrow transplantation: implications for cure.N Engl J Med. 1999;341:14–21.
Champlin R, Ho W, Gale RP. Antithymocyte globulin treatment in patients with aplastic anemia: a prospective randomized trial.N Engl J Med. 1983;308:113–118.
Doney K, Pepe M, Storb R, et al. Immunosuppressive therapy of aplastic anemia: results of a prospective, randomized trial of antithymocyte globulin (ATG), methylprednisolone, and oxymetholone to ATG, very high-doe methylprednisolone, and oxymetholone.Blood. 1992;79:2566–2571.
Frickhofen N, Joachim PK, Schrezenmeier H, et al. Treatment of aplastic anemia with antilymphocyte globulin and methylprednisolone with or without cyclosporine. The German Aplastic Anemia Study Group.N Engl J Med. 1991;324:1297–1304.
Marsh J, Schrezenmeier H, Marin P, et al. Prospective randomized multicenter study comparing cyclosporine alone versus the combination of antithymocyte globulin and cyclosporine for treatment of patients with nonsevere aplastic anemia: a report from the European Blood and Marrow Transplant (EBMT) Severe Aplastic AnemiaWorking Party.Blood. 1999;93:2191–2195.
McGlave PB, Haake R, Miller W, Kim T, Kersey J, Ramsay NK. Therapy of severe aplastic anemia in young adults and children with allogeneic bone marrow transplantation.Blood. 1987;70:1325–1330.
Sanders JE, Storb R, Anasetti C, et al. Marrow transplant for children with severe aplastic anemia.Am J Pediatr Hematol Oncol. 1994;16:43–49.
Kaplan EL, Meier P. Non-parametric estimation for incomplete observation.J Am Stat Assoc. 1958;53:457.
Paquette RL, Tebyani N, Frane M, et al. Long-term outcome of aplastic anemia in adults treated with antithymocyte globulin: comparison with bone marrow transplantation.Blood. 1995;85:283–290.
Doney K, Leisenring W, Storb R, Appelbaum FR. Primary treatment of acquired aplastic anemia: outcomes with bone marrow transplantation and immunosuppressive therapy.Ann Intern Med. 1997;126:107–115.
Marsh JCW, Hows JM, Bryett KA, et al. Survival after antilymphocyte globulin therapy for aplastic anemia depends on disease severity.Blood. 1987;70:1046–1052.
Bacigalupo A, Hows J, Gluckman E, et al. Bone marrow transplantation versus immunosuppression for the treatment of severe aplastic anemia (SAA): a report of the EBMT SAA Working Party.Br J Haematol. 1988;70:177–182.
Socie G, Henry-Amar M, Bacigalupo A, et al. Malignant tumors occurring after treatment of aplastic anemia. European Bone Marrow Transplantation-Severe Aplastic Anemia Working Party.N Engl J Med. 1993;329:1152–1157.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Ahn, MJ., Choi, JH., Lee, YY. et al. Outcome of Adult Severe or Very Severe Aplastic Anemia Treated with Immunosuppressive Therapy Compared with Bone Marrow Transplantation: Multicenter Trial. Int J Hematol 78, 133–138 (2003). https://doi.org/10.1007/BF02983381
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF02983381